My Profile

Search abstracts

Lewis Sheiner

Stockholm, Sweden

Montreux, Switzerland

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

KÝbenhavn, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

Printable version


Tuesday June 8


16:00-20:00 Registration
18:00-20:00 Welcome reception


Wednesday June 9


08:00-08:45 Registration
08:45-09:00 Welcome and Introduction
09:00-10:20 Physiology based modelling

chair: Charlotte Kloft 

09:00-09:40 Wilhelm Huisinga Physiologically-based pharmacokinetic/pharmacodynamic modelling, mathematical model reduction and a mechanistic interpretation of simple empirical models
09:40-10:00 Martin Bergstrand Semi-mechanistic modeling of absorption from extended release formulations - linking in vitro to in vivo
10:00-10:20 Stefan Willmann Investigation of the Influence of CYP3A4 Inhibition and Renal Impairment on Morphine and M6G Formation after Codeine Administration using Coupled Whole-Body PBPK Modelling
10:20-11:50 Coffee break, Poster and Software session I
  Posters in Group I (see below) are accompanied by their presenter
11:50-12:30 Physiology based modelling (continued) chair: Katya Gibiansky 
11:50-12:10 Pascal Chanu Mechanistic Models to Simulate Dose Response of IgE Suppression Following Dosing of Anti-IgE Monoclonal Antibodies
12:10-12:30 Julia Korell Design of survival studies for red blood cells
12:30-14:00 Lunch
14:00-15:15 Covariate model building chair: Mats Karlsson 
14:00-14:55 Stephen Senn Tutorial: Covariate complications in clinical trials
14:55-15:15 Akash Khandelwal Covariate Model Building Using Linear Approximations
15:15-16:30 Tea break, Poster and Software session II
  Posters in Group II (see below) are accompanied by their presenter
16:30-17:30 Methodology chair: France Mentré 
16:30-16:50 Brigitte Lacroix Evaluating the IPPSE method for PKPD analysis
16:50-17:10 Dalia Khachman You have problems to interpret VPC? Try VIPER!
17:10-17:30 Bruno Boulanger Trial predictions vs. trial simulations in early clinical development: a framework to evaluate the predictive probability of success based on NONMEM outputs


Thursday June 10


08:45-10:05 Lewis Sheiner Student Session

chairs: Chantal Csajka, Ferdie Rombout, Willi Weber  

08:45-09:10 Caroline Bazzoli Design evaluation and optimisation in multi-response nonlinear mixed effect models with cost functions: application to the pharmacokinetics of zidovudine and its active metabolite
09:10-09:35 Maud Delattre Estimation of mixed hidden Markov models with SAEM. Application to daily seizures data
09:35-10:00 Lay Ahyoung Lim Dose-response-dropout analysis for somnolence in Pregabalin-treated patients with generalized anxiety disorder
10:00-10:05 Presentation of Awards  
10:05-11:20 Coffee break, Poster and Software session III
  Posters in Group III (see below) are accompanied by their presenter
11:20-12:20 Clinical applications of PK(PD) chair:  Dinesh de Alwis
11:20-11:40 Chao Zhang Population Pharmacokinetics of Lopinavir/Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Children 
11:40-12:00 Jeff Barrett Enhancing Methotrexate Pharmacotherapy in Children with Cancer: A Decision Support System Integrating Real-time PK/PD Modeling and Simulation with Patient Medical Records
12:00-12:20 Sarah McLeay Exploring different body-size metric based dosing strategies for propofol in morbidly obese versus healthy weight subjects by modelling and simulation approach
12:20-13:50 Lunch
13:50-15:15 Integrating data with literature chair: Lutz Harnisch 
13:50-13:55 Lutz Harnisch Introduction to integrating data with literature
13:55-14:15 Eugene Cox Meta- Analysis of Retention Rates of Post-Marketing Trials to Compare Effectiveness of Second Generation Antiepileptic Drugs
14:15-14:35 Rocío Lledó-García A mechanistic model of the steady-state relationship between HbA1c and average glucose levels in a mixed population of healthy volunteers and diabetic subjects
14:35-15:15 Jonathan French When and how should I combine patient-level data and literature data in a meta-analysis?
15:15-16:30 Tea break, Poster and Software session IV
  Posters in Group IV (see below) are accompanied by their presenter
16:30-17:10 Design chair: Marylore Chenel 
16:30-16:50 Camille Vong Rapid sample size calculations for a defined likelihood ratio test-based power in mixed effects models
16:50-17:10 Lee Kien Foo D-optimal Adaptive Bridging Studies in Pharmacokinetics
19:00-01:00 Social evening


Friday June 11


09:00-10:00 Stuart Beal Methodology Session chair: Oscar della Pasqua 
09:00-09:20 Marc Lavielle Mixture models and model mixtures with MONOLIX
09:20-09:40 Matthew Hutmacher Extending the Latent Variable Model to Non-Independent Longitudinal Dichotomous Response Data
09:40-10:00 Elodie Plan Analysis Approaches Handling Both Symptomatic Severity and Frequency
10:00-10:10 Preview of PAGE 2011
10:10-10:50 Coffee Break
10:50-12:10 PKPD models chair: Nick Holford 
10:50-11:10 Sylvain Goutelle Mathematical modeling of pulmonary tuberculosis therapy: development of a first prototype model with rifampin
11:10-11:30 Alberto Russu Integrated model for clinical response and dropout in depression trials: a state-space approach
11:30-11:50 Klas Petersson Predictions of in vivo prolactin levels from in vitro Ki values of D2 receptor antagonists using an agonist-antagonist interaction model
11:50-12:10 Rada Savic Adherence and Population Pharmacokinetics of Atazanavir in Naïve HIV-Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing
12:10-12:20 Closing Remarks
12:20-12:50 Audience Input for the PAGE 2011 Program



Software demonstrations-Commercial

S_1: Stephane Vellay Pipeline Pilot - Data Integration, Analysis, and Reporting Platform
S_2: Masoud Jamei Simcyp Simulator - a comprehensive platform and database for mechanistic modelling and simulation of drug absorption, tissue distribution, metabolism, transport and elimination in healthy and disease populations using in vitro knowledge
S_3: Sven Janssen SimBiology: A Graphical Environment for Population PK/PD

Software demonstrations-Non-commercial

S_10: Juergen Bulitta Development and Evaluation of a New Efficiency Tool (SADAPT-TRAN) for Model Creation, Debugging, Evaluation, and Automated Plotting using Parallelized S-ADAPT, Perl and R
S_11: Kajsa Harling Xpose and Perl speaks NONMEM (PsN)
S_12: Roger Jelliffe The MM-USCPACK software for nonparametric adaptive grid (NPAG) population PK/PD modeling, and the MM-USCPACK clinical software for individualized drug regimens.
S_13: Ron Keizer Piraña: Open source modeling environment for NONMEM
S_14: Marc Lavielle Analysing population PK/PD data with MONOLIX 3.2
S_15: Sebastian Ueckert PopED - An optimal experimental design software


Posters Wednesday Morning (group I)

Applications- Anti-infectives
I_1: Bambang Adiwijaya Applications of Discrete-Event Dynamic Simulation in HCV Treatment Dynamics
I_2: Jurgen Bulitta Mechanism-based Modelling of the Synergy of Colistin Combinations against Multidrug-Resistant Gram Negative Bacteria
I_4: Emmanuel Chigutsa Parallel first order and mixed order elimination of pyrazinamide in South African patients with tuberculosis
I_5: Isabelle Delattre Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin in critically ill septic patients
I_6: Oleg Demin Application of systems pharmacology modeling approach to optimize Interferon therapy of hepatitis C
I_7: Thomas Dorlo Optimal Dosing of Miltefosine in Children and Adults with Leishmaniasis

Applications- Biologicals/vaccines
I_8: Marion Dehez Bayesian framework applied to dose escalation studies for biologics 
I_9: Amit Garg A Mechanism Based Population Pharmacokinetic-Pharmacodynamic Model for Epoetin Alfa and Darbepoetin Alfa in Chronic Kidney Disease Patients 
I_10: Kenneth Luu A Mechanistic Approach to Predicting Human Pharmacokinetics of Monoclonal Antibodies from Preclinical Data: A Case Example
I_11: David Ternant Methotrexate influences neither pharmacokinetics nor concentration-effect relationship of infliximab in axial ankylosing spondylitis
I_12: Pawel Wiczling Pharmacokinetics and Pharmacodynamics of Anti-CD3 Monoclonal Antibody, Otelixizumab, in Subjects with Diabetes and Psoriasis 

Applications- CNS
I_13: Neil Attkins Model based analysis of antagonist binding kinetics at CRF-1 receptors in vitro and in vivo
I_14: Marcus Björnsson Modeling of Pain Intensity Measured on a Visual Analogue Scale and Informative Dropout in a Dental Pain Model after Naproxcinod and Naproxen Administration
I_15: Jacob Brogren Transit Compartment Model Useful for Describing Absorption of Quetiapine XR and IR
I_16: Yu-Yuan Chiu Population Pharmacokinetics of Lurasidone in Healthy Subjects and Subjects with Schizophrenia
I_17: Vincenzo Luca Di Iorio Impact of Seizures and Efflux Mechanisms on the Biophase Kinetics and CNS Effects of Anticonvulsant Drugs 

Applications- Oncology
I_18: Nicolas Azzopardi Pharmacokinetics and concentration-effect relationship of cetuximab in metastatic colorectal cancer
I_19: Anne Drescher Pharmacokinetic/Pharmacodynamic Modeling of Platinum-DNA-Adduct Formation in Leukocytes after Oxaliplatin Infusion
I_20: Jeroen Elassaiss-Schaap Allometric scaling in oncology disease progression from xenograft tumor growth to human non-small-cell lung cancer
I_21: Iñaki F. Trocóniz Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies using diflomotecan and indisulam 
I_22: Ron Keizer Evaluation of clinical dosing of E7820 from preclinical and clinical data using a biomarker

Applications- Other topics
I_23: Claire Ambery Leveraging biomarker exposure-response in drug development
I_24: Jacqueline Anderson PK modelling of organophosphorus poisoning in humans
I_25: Massoud Boroujerdi Joint model for dropout in longitudinal trials in COPD patients
I_26: Karl Brendel Population pharmacokinetics-pharmacodynamics modeling of the QTc prolongation of Moxiflovoxacin and Levofloxacin in healthy volunteers: selection of the positive control in mandatory QT/QTc studies
I_27: Karl Brendel Using Modelling & Simulation techniques to optimise the design of a paediatric PK/PD study
I_28: Sophie Callies Integration of preclinical data to support the design of the first in-man study of LY2181308, a second generation antisense oligonucleotide.
I_29: Roosmarijn De Cock Predicting glomerular filtration rate using clearance of amikacin
I_30: Oleg Demin Jr Can systems modeling approach be used to understand complex PK-PD relationships? A case study of 5-lipoxygenase inhibition by zileuton
I_31: Pinky Dua SB-773812: Correlation between in-silico and in-vivo metabolism

Methodology- Model evaluation
I_32: Roberto Bizzotto Multinomial logistic functions in Markov-chain models for modeling sleep architecture: external validation and covariate analysis
I_33: Roberto Bizzotto PK-PD modeling of Wake after Sleep Onset time-course
I_34: Roberto Bizzotto Multinomial logistic functions in Markov-chain models for modeling sleep architecture: internal validation based on VPCs
I_35: Emmanuelle Comets Using simulations-based metrics to detect model misspecifications
I_36: Didier Concordet A new solution to deal with eta-shrinkage: the Weighted EBEs!
I_37: Paul Matthias Diderichsen A comparison of sequential and joint fitting of pain intensity and dropout hazard in acute pain studies
I_38: Paul Matthias Diderichsen Sufficiently high observation density justifies a sequential modeling approach of PKPD and dropout data

Methodology- Other topics
I_39: Margherita Bennetts Simulation Methodology for Quantitative Study Decision Making in a Dose Response Setting
I_40: Paul Baverel Informativeness of Internal and External Validation Techniques in Various Simulation Settings
I_41: Julie Bertrand Genetic effect on a complex parent-metabolite joint PK model developed with NONMEM and MONOLIX
I_42: Martin Boucher Imputation of missing variance data comparing Bayesian and Classical non- linear mixed effect modelling to enable a precision weighted meta-analysis.
I_43: Olivier Colomban Toxicogenomic dose-response model assessed by DNA chips on rats treated by flutamide
I_44: Paolo Denti Modelling pre-dose concentrations in steady-state data. The importance of accounting for between-occasion variability and poor adherence.
I_45: Gemma Dickinson Evaluation of a Method to Better Predict Human Absorption from Non-Clinical Data; Comparison of an in silico approach with population modelling of in vivo data
I_46: Aris Dokoumetzidis Fractional kinetics in multi-compartmental systems

Methodology- PBPK
I_47: Hesham Al-Sallami A semi-mechanistic model for estimating lean body weight in children
I_48: Marilee Andrew Physiologically Based Pharmacokinetic (PBPK) Modeling of Midazolam Disposition in Pregnant and Postpartum Women
I_49: Karina Claaßen Physiology-based Simulations of Amikacin Pharmacokinetics in Preterm Neonates

Late submissions
I_50: Gudrun Wuerthwein Population Pharmacokinetics of Liposomal Amphotericin B, Caspofungin and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients
I_51: Peiming Ma Predicting Free Sclerostin from Free AMG 785 and Total Sclerostin
I_52: Leonid Gibiansky TMDD Model for Drugs that Bind Soluble and Membrane-Bound Targets: Can Quasi-Steady-State Approximation Estimate unobservable Membrane-Bound Target Occupancy?
I_53: Ronald Niebecker Impact of Different Body Size Descriptors on the Population Pharmacokinetics of a Monoclonal Antibody

Posters Wednesday Afternoon (group II)

Applications- Anti-infectives
II_1: Monika Frank Population Pharmacokinetic Model Building for Mothers and Newborns using Additional Information from a Different Nevirapine Dataset
II_2: Jeremie Guedj Design Evaluation and Optimization for models of Hepatitis C viral dynamics
II_3: Seong Bok Jang Population Pharmacokinetics of Amikacin in Korean Clinical Population
II_4: Siv Jonsson Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients
II_5: Dalia Khachman Population pharmacokinetic analysis of ciprofloxacin in intensive care unit adult patients
II_6: Holly Kimko Modeling & Simulation Exercise to Recommend Dosage Regimens for Patients with End-Stage Renal Disease Receiving Hemodialysis 

Applications- CNS
II_7: Yuen Eunice A population pharmacokinetic/pharmacodynamic model for duloxetine in diabetic peripheral neuropathy, plus methods for handling missing data.
II_8: Martin Gnanamuthu Johnson Evaluation of a Mechanism-Based Pharmacokinetic-Pharmacodynamic Model for D2 Receptor Occupancy of Olanzapine in Rats
II_9: Gordon Graham Continuous time Markov modelling of relapse sojourns for relapse-remitting multiple sclerosis patients
II_10: Andrew Hooker Title: Modeling exposure-response relationships in the rat self-administration model
II_11: Matts Kågedal Estimation of occupancy and radioligand kinetics in the CNS from PET-data in the absence of a reference region.
II_12: Kristin Karlsson Clinical trial simulations using a stroke disease progression model

Applications- CVS
II_13: Anne Chain Not-in trial simulation: Prospective use of Not-In-Trial simulation
II_14: Carolyn Coulter Prediction of Torsades de Pointes from QT interval: analysis of a case series with amisulpride 
II_15: Vincent Dubois Translation of drug-induced QTc prolongation in early drug development.
II_16: Anne-Kristina Frobel Physiologically-Based Pharmacokinetic (PBPK) Modelling of Bisoprolol in Adults and Children and External Model Validation in a Paediatric Clinical Trial
II_17: Florence Hourcade-Potelleret Preliminary Population PK-PD of Dalcetrapib: an Agent Targeting CETP to Raise HDL-C and Prevent Cardiovascular Morbidity and Mortality 
II_18: Sergej Ramusovic An integrated whole-body physiology based pharmacokinetic/pharmacodynamic model of enalapril and the RAA-system

Applications- Oncology
II_19: Martin Fransson Pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model
II_20: Maria Garrido Population pharmacokinetic modelling of unbound and total plasma concentrations of oxaliplatin administered by hepatic arterial infusion to patients with liver-metastases.
II_21: Kimberley Jackson A Novel PKPD Model to Describe the Interaction of Drug Response of Combination Therapy: An Application in Preclinical Oncology.
II_22: Fredrik Jonsson A Longitudinal Tumor Growth Inhibition Model Based on Serum M-Protein Levels in Patients With Multiple Myeloma Treated by Dexamethasone 

Applications- Other topics
II_23: Anne Dubois Model-based bioequivalence analysis of recombinant human growth hormone using the SAEM algorithm: liquid or lyophilized formulations of Omnitrope® versus original lyophilized Genotropin®
II_24: Anne Dubois Model-based bioequivalence analysis of pharmacokinetic crossover trial compared to standard non-compartmental analysis
II_25: Iñaki F. Trocóniz Population PK/PD model of the sedative effects of Flibanserin in healthy volunteers
II_26: Martin Fink Phase I trials: Model-based assessment to identify a clinical relevant change in heart rate
II_27: Nils Ove Hoem A population PK model of EPA and DHA after intake in phospholipid as well as in triglyceride form.
II_28: Ibrahim Ince Critical illness is a major determinant for midazolam and metabolite clearance in children

Methodology- Algorithms
II_29: Jeff Barrett A SAS-based Solution for NONMEM run management and post-processing 
II_30: Mike Dunlavey Derivation of SAEM C-matrix in Phoenix
II_31: Marc Gastonguay Comparison of MCMC simulation results using NONMEM 7 or WinBUGS with the BUGSModelLibrary
II_32: Leonid Gibiansky Bias and Precision of Parameter Estimates: Comparison of Nonmem 7 Estimation Methods and PFIM 3.2 Predictions on the Example of Quasi-Steady-State Approximation of the Two-Target Target-Mediated Drug Disposition Model
II_33: Åsa Johansson New Estimation Methods in NONMEM 7: Evaluation of Bias and Precision 

Methodology- Design
II_34:Caroline Bazzoli New features for population design evaluation and optimisation using PFIM3.2: illustration on warfarin pharmacokinetics - pharmacodynamics
II_35: Chao Chen Test Of Concept By Simulation: Comparing Response-Rate Findings Between Parallel And Titration Designs
II_36: Marylore Chenel Optimal design and QT-prolongation detection in oncology studies 
II_37: Nicolas Frances Influence analysis explores heterogeneity in database before data processing by a parametric population method
II_38: Thu Thuy Nguyen Design evaluation and optimisation in crossover pharmacokinetic studies analyzed by nonlinear mixed effects models

Methodology- Model evaluation
II_39: Julie Grenier Population Pharmacokinetic and Pharmacodynamic Meta Analysis of Zenvia: Modeling of QT Prolongation
II_40: Julie Grenier Population Pharmacokinetic Meta Analysis: Inhibition by Quinidine of the First-Pass and Systemic Metabolism of Dextromethorphan to Dextrorphan
II_41: Chiara Piana The Influence Of Covariate Distribution On The Prediction And Extrapolation Of Pharmacokinetic Data In Children.

Methodology- Other topics
II_42: Charles Ernest Predictor Identification in Time-to-Event Analyses
II_43: Farkad Ezzet Analysis of Adverse Events using Literature Data: a Simulation Study
II_44: Farkad Ezzet Modeling Adverse Event rates of Opioids for the Treatment of Osteoarthritis Pain using Literature Data
II_45: Farkad Ezzet Bronchial Allergen Challenge in Asthma: A Model for Inhaled Corticosteroids (ICS) and Montelukast using Literature Summary Data
II_46: Roberto Gomeni Integrated approach to overcome a food effect in clinical studies: an example of how in vitro, in vivo and simulation tools can help in determining an appropriate strategy
II_47: Thaddeus Grasela Forensic Pharmacometrics: Part 1 - Data Assembly
II_48: Thaddeus Grasela Forensic Pharmacometrics: Part 2 - Deliverables for Regulatory Submission
II_49: Ivelina Gueorguieva Is pharmacokinetic variability in microdosing trials comparable to variability following therapeutic doses?
II_50: Michael Heathman Interactive Simulation and Visualization of Drug/Disease Models
II_51: Roger Jelliffe Pharmacogenomics and Individualized Dosage Regimens
II_52: Ron Keizer Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses


Posters Thursday Morning (group III)

Applications- Anti-infectives
III_1: Maria Kjellsson Penetration of Isoniazid, Rifampicin, Pyrazinamid and Moxifloxacin into Pulmonary TB Lesions in Rabbits
III_2: Michael Neely High-dose amoxicillin pharmacokinetics (PK) and pharmacodynamics (PD) in children
III_3: Thu Thuy Nguyen Population pharmacokinetic of linezolid in inpatients
III_4: Elisabet Nielsen Pharmacokinetic-Pharmacodynamic Modelling for Antibiotics: Static and Dynamic In Vitro Time-Kill Curve Experiments 

Applications- CNS

III_5: Magdalena Kozielska Predictive performance of two PK-PD models of D2 receptor occupancy of the antipsychotics risperidone and paliperidone in rats

III_6: SeungHwan Lee A population analysis of Intravenous Dexmedetomidine in Korean

III_7: Gailing Li Towards Quantitative Prediction Of In Vivo Brain Penetration Using A Physiology Based CNS Disposition Model

III_8: Venkatesh Pilla Reddy Modeling and Simulation of Placebo Response and Dropout Patterns in Treatment of Schizophrenia

Applications- Oncology
III_9: Cornelia Landersdorfer Pharmacodynamic (PD) Modelling of Anti-Proliferative Effects of Tetraiodothyroacetic Acid (Tetrac) on Human Cancer Cells
III_10: Valerie Nock Leukopenia following high-dose chemotherapy with autologous stem cell retransfusion in patients with testicular cell cancer

Applications- Other topics
III_11: Elke Krekels Paracetamol pharmacokinetics in term and preterm neonates.
III_12: Yoon Jung Lee Model-based evaluation of DAS28 as a potential surrogate for ACR20 to establish the dose-response relationship for disease modifying anti-rheumatic drugs. A case study using tasocitinib (CP-690,550), an oral JAK inhibitor.
III_13: Ivan Matthews PKPD Modeling of Dose-Response & Time Course of B-Cell Depletion in Cynomolgus Monkeys 
III_14: Jebabli Nadia Population Pharmacokinetics Of Vancomycin In Tunisian Patients
III_15: Jebabli Nadia Pharmacokinetic Modelling Of Methotrexate From Routine Clinical Data In Patients With Acute Lymphoblastic Leukemia
III_16: Jebabli Nadia Effect Of Clonidine On Bupivacaine Clearance In Tunisian Patients: Population Pharmacokinetic Investigation.
III_17: Chiara Piana Once Daily Pharmacokinetics Of Lamivudine In HIV-Infected Children

Methodology- Algorithms
III_18: Marc Lavielle The SAEM algorithm for Non-Linear Mixed Effects Models with Stochastic Differential Equations
III_19: Robert Leary Quasi-Monte Carlo EM Methods for NLME Analysis
III_20: Hafedh Marouani Nonparametric Approach using Gaussian Kernels Estimates Multivariate Probability Densities in Population Pharmacokinetics
III_21: Ines Paule Estimation of Individual Parameters of a Mixed–Effects Dose-Toxicity Model for Ordinal Data
III_22: Elodie Plan Nonlinear Mixed Effects Estimation Algorithms: A Performance Comparison for Continuous Pharmacodynamic Population Models 
III_23: Sebastian Ueckert New Estimation Methods in NONMEM 7: Evaluation of Robustness and Runtimes

Methodology- Design
III_24: Sergei Leonov Optimization of sampling times for PK/PD models: approximation of elemental Fisher information matrix
III_25: Flora Musuamba-Tshinanu An optimal designed study for population pharmacokinetic modeling and Bayesian estimation of Mycophenolic acid and Tacrolimus early after renal transplantation 
III_26: Flora Musuamba-Tshinanu Evaluation of disease covariates in chronic obstructive pulmonary disease (COPD).
III_27: Coen van Hasselt Application of a semi-physiological model describing time-varying pharmacokinetics to support optimal clinical study design
III_28: Joakim Nyberg Global, exact and fast group size optimization with corresponding efficiency translation in optimal design

Methodology- Model evaluation
III_29: Joakim Nyberg Investigations of the weighted residuals in NONMEM 7
III_30: Mary Lor Modeling and Simulation of Drug X and its Metabolite in Plasma and Urine

Methodology- Other topics
III_31: William Knebel A Strategy for Efficient Implementation of NONMEM 7 and the Intel Fortran Compiler in a Distributed Computing Environment
III_32: Brigitte Lacroix Simultaneous modeling of the three ACR improvement thresholds – 20, 50 and 70% - in rheumatoid arthritis patients treated with certolizumab pegol
III_33: Otilia Lillin-de Vries Population PK-PD modeling of thorough QT/QTc data allows for mechanistic understanding of observed QTc effects
III_34: Igor Locatelli The Development of a Link Model Consisting of in vitro Drug Release and Tablets Gastric Emptying Time: Application to Diclofenac Enteric Coated Tablets
III_35: Christophe Meille Probabilistic PK/PD model for ordered categorical toxicological data
III_36: Eugeniy Metelkin Application of pharmacokinetic-pharmacodynamic model to optimize dosing regime of antimicrobial drug Grammidin containing gramicidin S
III_37: Carmen Navarro Bioequivalence trials simulation to select the best analyte for drugs with two metabolic pathways
III_38: Ackaert Oliver A true Markov model for sleep disturbance
III_39: Henry Pertinez Bayesian POP-PK analysis of exposure data from a Phase IIb clinical trial
III_40: Leonid Gibiansky Target-Mediated Drug Disposition: New Derivation of the Michaelis-Menten Model, and Why It Is Often Sufficient for Description of Drugs with TMDD

Methodology- PBPK
III_41: Wojciech Krzyzanski An Interpretation of Transit Compartment Pharmacodynamic Models As Lifespan Based Indirect Response Models.
III_42: Jörg Lippert Clinical trial simulation with multiscale models: Integrating whole-body physiology, disease biology, and molecular reaction networks
III_43: Jörg Lippert Separating individual physiological variability from drug related properties using PBPK Modeling with PK-Sim® and MoBi® – Theophylline
III_44: Jörg Lippert Using relative gene expression measurements for PBPK modeling of pravastatin
III_45: Jörg Lippert Identifying cancer drug MoAs and cell-line properties using signaling cascade models and Bayesian analysis: From throw-away experiments to persistent information
III_46: Jörg Lippert Mechanistic analysis of fusion proteins: PBPK applied in an Albuferon case study
III_47: Jörg Lippert Influence of CYP1A1 induction by cigarette smoke on pharmacokinetics of erlotinib: a computer-based evaluation of smoke-induced CYP1A1 activity in different tissues
III_48: Jörg Lippert Simulation of the pharmacokinetics of flibanserin under itraconazole co-mediaction with an integrated physiologically-based pharmacokinetic model
III_49: Zinnia Parra Nonlinear Pharmacokinetic Model For Interleukin-12 Gene Therapy
III_50: Sabine Pilari Lumping of Physiologically Based Pharmacokinetic Models and a Mechanistic Derivation of Classical Compartmental Models 


Posters Thursday Afternoon (group IV)

Applications- Anti-infectives
IV_1: Rada Savic Ciprofloxacin Integrated Plasma, Saliva and Sweat Population Pharmacokinetics and Emergence of Resistance in Human Commensal Bacteria
IV_2: Wynand Smythe A Semi-Mechanistic pharmacokinetic enzyme model for the characterisation of rifampicin pharmacokinetics in South African pulmonary tuberculosis infected adults
IV_3: Ami Fazlin Syed Mohamed Predictions of Dosing Schedules of Gentamicin in Neonates Based on a Pharmacokinetic/Pharmacodynamic Model Considering Adaptive Resistance
IV_4: Joel Tarning Population pharmacokinetics of antimalarial drugs in the treatment of pregnant women with uncomplicated malaria
IV_5: Toshihiro Wajima Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling for Integrase Inhibitors with a Simple Viral Dynamic Model
IV_6: Simbarashe Peter Zvada Effect of Four Different Meals Types on the Population Pharmacokinetics of single Dose Rifapentine in Healthy Male Volunteers 

Applications- CNS

IV_7: Mahesh Samtani Switching to Paliperidone Palmitate[1,2] from Other Depot Antipsychotics: Guidance Based on Pharmacokinetic Simulations

IV_8: Monica Simeoni Clinical and Genetic factors affecting Alzheimer’s disease progression in subjects on stable acetylcholinesterase inhibitor therapy: a comparison between mechanistic and empirical disease progression modelling approaches

IV_9: Monica Simeoni Disease System Analysis: Evaluate the structural properties and the physiological implications of an indirect physiologic response model describing the degenerative progression of Alzheimer’s disease using a closed-form solution

IV_10: Armel Stockis Exposure-response modeling of daily seizure counts in focal epilepsy trials

IV_11: Mita Thapar Population Pharmacokinetics of Safinamide and its Effect on Disease Progression in Parkinson's Disease

IV_12: Pyry Välitalo Plasma and Cerebrospinal Fluid Pharmacokinetics of Naproxen in Children

IV_13: Marcel van den Broek Optimal dosing of lidocaine for seizure control in preterm and term neonates using population pharmacokinetic modelling and simulation

IV_14: Anders Viberg Using an Innovative Design in Behavioural Pharmacology Studies Saves Money and Animal Lives

IV_15: Stefano Zamuner The assessment of convulsion risk: a translational PK/PD modelling approach

Applications- Coagulation
IV_16: Anna-Karin Hamberg Internal and external evaluation of a K-PD model for warfarin using prediction corrected visual predictive check (PC-VPC) 
IV_17: Hesham Al-Sallami A rationale for the routine monitoring of anti-activated factor X (anti-Xa) during enoxaparin treatment 

Applications- Endocrine
IV_18: Anna Largajolli Assessment of the oral glucose minimal model by nonlinear mixed-effects approaches 
IV_19: Elba Romero Development of a mechanistic-based pharmacodynamic model to describe the effect of a prolonged administration of a GnRH agonist on testosterone levels

Applications- Oncology
IV_20: Benjamin Ribba Combined analysis of tumor size data and histological biomarkers drives the development of a semi-mechanistic model of the effect of the antiangiogenic drug Sunitinib in mice
IV_21: Hauke Ruehs Homocysteine as biomarker in a semi-mechanistic PK/PD model of methotrexate
IV_22: Alexandre Sostelly Modelling the interaction between Irinotecan and efflux transporters inhibitors: A KPD tumour growth inhibition model including interaction components.
IV_23: Herbert Struemper Analysis of Biomarker Responses in Phase I Study of rhIL-18 in Combination with Rituximab in Non-Hodgkin’s Lymphoma to Support Phase 2 Dose Selection
IV_24: Hoai Thu Thai A mechanism-based model for the population pharmacokinetics of aflibercept in healthy subjects
IV_25: Mirjam Trame External Evaluation of a Population Pharmacokinetic Model for Dosing Busulfan in Children – Body Surface Area better than Body Weight
IV_26: Kellie Turner Cyclophosphamide, Methotrexate, and 5-Fluorouracil Population Pharmacokinetic Models with Pharmacogenetic Covariates
IV_27: Federico Verga Modeling of the metastatic variability in cancer disease.
IV_28: Christian Woloch Population Pharmacokinetics of 5FU and its Major Metabolite 5-FDHU in Colorectal Cancer Patients
IV_29: Alena Zhang Evaluating the Extent of Chemotherapeutic Contamination from Central Venous Catheters in Children with Cancer and Providing Guidance for Accurate Reporting of PK Parameters

Applications- Other topics
IV_30: Didier Renard A trial simulation example to support the design and model-based analysis of a new dose and regimen finding study
IV_31: Jan-Stefan van der Walt A population model describing the pharmacokinetics of iv esomeprazole in patients aged 0 to 17 years, inclusive
IV_32: Johan Wallin Internal and external validation with sparse, adaptive-design data for evaluating the predictive performance of a population pharmacokinetic model of tacrolimus
IV_33: Chenguang Wang Scaling clearance of propofol from preterm neonates to adults using an allometric model with a bodyweight-dependent maturational exponent

Methodology- Design
IV_34: Angelica Quartino Application of Optimal Design to Reduce the Sample Costs of a Dose-finding Study
IV_35: Sylvie Retout Bayesian modeling of a PK-PD relationship to support an adaptive dose-finding trial
IV_36: Amit Taneja Optimisation of experimental design for drug screening in behavioural models of pain.
IV_37: Donato Teutonico Development of a template for clinical trial simulations in COPD
IV_38: Sebastian Ueckert Comparison of Different Global Optimal Design Approximations
IV_39: Venkata Pavan Kumar Vajjah Generalisation of T-optimality for discriminating between competing models - an application to paracetamol overdose

Methodology- Model evaluation
IV_40: Italo Poggesi Modeling a time-dependent absorption constant: a trick and some considerations
IV_41: Stephan Schmidt Implication of differences in model parameterisation in osteoporosis
IV_42: Steven Xu A Casual Graphic Goodness-of-fit Assessment for Markov Pharmacodynamic Models

Methodology- Other topics
IV_43: Tarjinder Sahota Model-based safety thresholds for discrete adverse events
IV_44: Tarjinder Sahota The Chicken and the Egg in Interoccasion Variability
IV_45: Tobias Sing An R package for industrializing concentration-QT analysis
IV_46: Kuenhi Tsai Estimation Comparison of Pharmacokinetic Models Using MONOLIX, PKBUGS, and NONMEM
IV_47: Coen van Hasselt Implementation of an affordable computing cluster for pharmacometric analysis
IV_48: Paul Westwood A Pharmacokinetic Study of Ranitidine in a Paediatric Population
IV_49: Justin Wilkins A comparison of two model-based approaches to investigating covariate effects on the dose-exposure relationship in a Phase III context

Methodology- PBPK
IV_51: Cecile Gerard Influence of cyclosporin dosing schedule on receptor occupancy in bone marrow transplantation: analysis with a PBPK-PD model
IV_52: Julia Hövener Evaluation of a Physiologically-Based Pharmacokinetic (PBPK) Model for the Application of Low Dose Etoposide in Children 
IV_53: Kirstin Thelen A novel physiological model to simulate gastrointestinal fluid dynamics, transit of luminal contents, absorption, and pre-systemic metabolism of orally administered drugs in humans